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Abstract T cell activation plays a crucial role in the develop-
ment of acute graft versus host disease (aGvHD). Cytotoxic T
cell antigen-4 (CTLA-4) is a co-inhibitory molecule that neg-
atively regulates T cell activation, differentiation, and prolif-
eration. Single-nucleotide polymorphisms (SNPs) in CTLA-4
gene may affect its function. Inconsistent observations have
been reported regarding the associations of CTLA-4 SNPs
with complications after hematopoietic stem cell transplanta-
tion (HSCT). Moreover, the majority of the observations were
focused on the donors’ SNPs. Recently, a few studies have
shown that recipients’ genetic variations in the CTLA-4 gene
might influence HSCT results. The aim of our study was to
determine the influence of the CTLA-4 gene polymorphisms
of the donors and the recipients on the outcome of HSCT.
Altogether, 312 donor-recipient pairs were genotyped for the
CTLA-4c.49A>G (rs231775) and CT60G>A (rs3087243)
SNPs using the TaqMan®SNP Genotyping Assays. In this
study, it was shown that the recipients’ CT60G>A[GG] geno-
type, the myeloablative conditioning regimen, and HSCT
from an unrelated donor were independent aGvHD risk fac-
tors (odds ratio (OR) 2.63, 95 % confidence intervals (95 %
CI) 1.45–4.59, p=0.001; OR 2.68, 95 % CI 1.65–4.07, p=
0.00003; and OR 1.87, 95 % CI 1.02–3.24, p=0.04, respec-
tively). Moreover, haplotype analysis revealed that possessing
allele A in both of the SNPs decreased the risk of aGvHD
approximately 1.5-fold (RR 0.69, p=0.008). Our data suggest
that the CT60G>A[GG] genotype in the recipient has an im-
pact on aGvHD development, especially in patients receiving
transplants from unrelated donors together with the
myeloablative conditioning regimen.
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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is
used as a curative therapy for a large number of malignant and
non-malignant hematologic diseases. One of the major com-
plications after HSCT remains acute graft versus host disease
(GvHD), with its occurrence and severity being directly relat-
ed to the degree of human leukocyte antigen (HLA) incom-
patibility. The recognition of foreign HLA antigens is the first
and key element for T cell activation, but the effective activa-
tion requires a second signal, termed co-stimulation
(Frauwirth and Thompson 2002). CD28 is the primary T cell
co-stimulatory molecule, and it regulates Tcell differentiation,
cytokine secretion, proliferation, and survival (Salomon and
Bluestone 2001). Cytotoxic Tcell antigen-4 (CTLA-4), anoth-
er member of the CD28 family, plays an inhibitory role in the
early and late stages of T cell activation (Walunas et al. 1994).
Ligation of CTLA-4 with its ligands, CD80 or CD86, inhibits
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the cell cycle and the activity of the transcription factors
NF-κΒ, NF-AT, and AP-1 (Valk et al. 2008).
Because protein synthesis depends on the rate of gene tran-
scription and/or translation, polymorphisms existing in func-
tional sites of genes may affect their expression and function.
Several polymorphisms of the CTLA-4 gene have been found
to influence the expression level and function of the CTLA-4
protein and to dysregulate the trafficking of CTLA-4 within
cellular compartments (Anjos et al. 2002;Chistiakov et al.
2006;Kouki et al. 2000;Ligers et al. 2001;Wang et al. 2002).
Moreover, the CTLA-4 gene has been described as a suscep-
tibility locus for autoimmune and neoplastic diseases
(Ch i s t i akov and Turaku lov 2003 ;Gough e t a l .
2005;Kavvoura et al. 2007;Ueda et al. 2003). An increasing
number of studies have demonstrated an important role for
polymorphisms in genes encoding co-stimulatory molecules
in organ transplantation (de Reuver et al. 2003;Gorgi et al.
2006;Wisniewski et al. 2006) and HSCT outcomes (Azarian
et al. 2007;Perez-Garcia et al. 2007; Sellami et al.
2011;Vannucchi et al. 2007).
Most of the HSCT studies have been focused on the donor
CTLA-4c.49A>G and CT60G>A gene polymorphisms and
the HSCToutcomes, and the results presented in those studies
were inconsistent. However, the functional role of those
single-nucleotide polymorphisms (SNPs) is well established.
The CTLA-4c.49A>G transition causes a Thr/Ala substitu-
tion in the leader peptide, which affects the inhibitory function
of CTLA-4 by influencing the rates of endocytosis, surface
trafficking, and intracellular/surface partitioning (Anjos et al.
2002;Kouki et al. 2000;Ligers et al. 2001).
Several reports indicate that presence of the G allele in the
CT60G>A SNP in the 3′UTR of the CTLA-4 gene is associ-
ated with the production of less messenger RNA (mRNA) for
the soluble isoform of CTLA-4 (sCTLA-4) compared with the
full-length form (fCTLA-4) (Perez-Garcia et al. 2007;Ueda
et al. 2003). Therefore, it is hypothesized that sCTLA-4
blocks the B7 binding by the fCTLA-4 isoform presented on
the surface of T cells and in this way prevents the transduction
of inhibitory signals and leads to the impaired inactivation of
T-cells.
Xiao et al. (Xiao et al. 2012) showed that upon stimulation,
peripheral blood mononuclear cells (PBMCs) carrying the
CT60G>A[GG] genotype exhibited significantly lower prolif-
eration than PBMCs carrying the CT60G>A[AA]/[GA]
genotypes.
Our earlier study of protein expression showed that the
percentage of cells expressing membrane CTLA-4 and cyto-
plasmic CTLA-4 in multiple sclerosis patients with the
relapsing-remitting form of the disease was higher for individ-
uals possessing CT60G>A[A+] alleles than those with the
CT60G>A[GG] genotype (Karabon et al. 2009).
Because donor T cells play the crucial role in acute graft
versus host disease (aGvHD) induction, the research on the
association between CTLA-4 gene polymorphisms and HSCT
outcomes was focused mainly on the polymorphisms in the
HSCT donors. However, recently, a few studies of the influ-
ence of the recipient CTLA-4 polymorphisms on the HSCT
outcome appeared in the literature (Mossallam and Samra
2013;Orru et al. 2012;Piccioli et al. 2010;Xiao et al. 2012).
In addition, our recent functional studies indicate that the
level of CTLA-4 in the recipient before transplantation affects
the aGvHD risk (Karabon et al. 2015).
Therefore, the aim of the present study was to evaluate the
association between two polymorphisms: CTLA-4c.49A>G




Altogether, 312 patients (146 F/166 M, median age 33 years,
range 18–57) transplanted in the Department of Hematology
and Bone Marrow Transplantation, Medical University of Si-
lesia, Katowice, between 2006 and 2010 and their donors
were included in this study.
Of the recipients, 108 underwent related donor (RD)
HSCTs, and 204 underwent unrelated donor (URD) HSCTs.
For nine recipients, a second transplantation was needed (the
second transplantation was RD in one case and URD in eight
cases).
Primary diagnoses were acute myeloid leukemia (148),
acute lymphoblastic leukemia (66), myelodysplastic syn-
drome (19), chronic myeloid leukemia (18), severe aplastic
anemia (17), paroxysmal nocturnal hemoglobinuria (11), and
other cases (33).
The source of the hematopoietic stem cells was bone mar-
row (BM) in 133 transplants, peripheral blood progenitor cells
(PBPC) in 171 cases, and both in 8 cases. For double trans-
plantations, the first source was BM, and the second was
PBPC.
Myeloablative conditioning (MAC) regimens were based
on cyclophosphamide with either busulfan or total body irra-
diation (TBI), or on melphalan, fludarabine, and
alemtuzumab. Reduced toxicity myeloablative conditioning
(RTMAC) was based on treosulfan and fludarabine or cyclo-
phosphamide. Reduced-intensity conditioning (RIC)
consisted of fludarabine and busulfan. Anti-thymocyte glob-
ulin (ATG) was used in all recipients of HSCT from unrelated
donors. The aplastic anemia patients received cyclophospha-
mide and ATG.
The Local Ethics Committee approved this study, and all
patients and controls gave their informed consent for the study
procedures.
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Determination of polymorphisms
Genomic DNAwas isolated from whole frozen blood using a
QIAamp® Blood mini kit (Hilden, Germany). The SNPs,
CTLA-4c.49A>G (rs231775) and CT60G>A (rs3087243),
were genotyped using the TaqMan®SNP Genotyping Assays
C__2415786_10 and C__3296043_10, respectively (Applied
Biosystems, Foster City, USA). Genotyping for SNPs was
validated using the RFLP technique described by
Daroszewski et al. (2009) and by sequencing. The correlation
between retyping methods was 99 % for CT60G>A and
CTLA-4c.49A>G.
Statistical analyses
The median was used as the location parameter. The Sn statis-
tic was computed as the measure of variability: Sn=med
{med|xi−xj|;j=1…n} (Rousseeuw P.J.and Croux C 1993). A
higher Sn value reflects higher variability. Additionally, the
first and third quartiles (Q), and minimal and maximal ob-
servations were reported. The probability of aGvHD was
modeled with a logistic model. The model coefficients and
their 95 % confidence intervals (95 % CIs) were estimated
based on B=4900 bootstrap samples. The R2 coefficient is
the fraction of the variation in the response variable ex-
plained by the model. The chi-square test, χ2df, was used
to test the null hypothesis that cases and controls have the
same distribution of genotype counts. In the case of small
numbers, the distribution of the test statistics was estimated
numerically. The odds ratio (OR) was computed as the mea-
sure of effect size. Departure from the Hardy-Weinberg equi-
librium (HWE) was tested with the chi-square test. Haplo-
type frequencies (HFs) among SNPs were estimated with a
maximum likelihood function (Excoffier and Slatkin 1995).
The measure for the estimation of pairwise linkage disequi-
librium (LD) was the squared correlation between two
SNPs, R2 (Excoffier and Slatkin 1995). For two SNPs, r
and R2 were obtained as r ¼ Di jﬃﬃﬃﬃﬃﬃpiq jp , where pi and qj are the
population allele frequencies of the ith allele on locus A and
the jth allele on locus B, Dij=xij−piqj and xij is the frequency
of the haplotype with alleles i and j on loci A and B, respec-
tively, R2 ¼ ∑2i ∑2j
D2i j
p; qj
. The likelihood ratio statistic, LRS,
was used to test for differences in haplotype frequencies
between cases and controls, LRS=2(LLcases+LLcontrols−
LLcombined).
To control for type I errors in the case of many tests for
differences between the SNP genotypes of cases and controls,
the adjusted significance level was estimated. Because of the




Acute GvHDwas diagnosed and graded according to the con-
sensus conference on aGvHD diagnosis (Przepiorka et al.
1995). Five patients died before day 30 after transplantation
and were excluded from the analysis. Acute GvHD grades 0,
1, 2, 3, and 4 appeared in 134, 122, 36, 8, and 5 HSCT recip-
ients, respectively. Data were not available for two patients.
The detailed characteristics of the recipients’ groups with and
without aGvHD are presented in Table 1.
In a univariate analysis, we examined the potential prognostic
variables, including the type of transplantation (RD or URD),
HLA matching, recipient age, donor age, sex mismatch, condi-
tioning regimen, and diagnosis. We found strong associations
between three variables and the risk of aGvHD: the HLA
matching, the conditioning regimen, and the type of allogeneic
HSCT. As expected, a disparity in HLA matching was strongly
associated with an increased risk of aGvHD (OR 2.11; 95 % CI
1.22–3.62; p=0.008). In addition, the conditioning regimen used
for HSCT was associated with the aGvHD risk. When we as-
sumed RIC conditioning as less associated with aGvHD risk,
then the OR for RTMAC was 1.50, whereas for MAC, the OR
was 4.50. In total, the aggressiveness of the conditioning regimen
was associated with the aGvHD risk with an OR of 2.40 (95 %
CI 1.65–3.48; p=0.00001). The RD HSCTwas associated with
approximately a twofold decrease in risk of aGvHD (OR 0.48;
95 % CI 0.29–0.78; p=0.004) compared to URD HSCT.
The sex of donors and recipients did not influence aGvHD
(p=0.85). The OR was similar for four donor-recipient sex
combinations (F→F, F→M, M→F, M→M). The age of
the donor and recipient had no impact on the aGvHD risk.
The average overall survival was similar in groups of patients
with and without aGvHD.
A CTLA-4 gene polymorphism study
No polymorphism data from donors and recipients demonstrated
any deviation from the Hardy-Weinberg equilibrium. We have
observed weak linkage disequilibrium between the CTLA-
4c.49A>G and CT60G>A polymorphisms in donors (R2=
0.49) and in recipients (R2=0.524). Haplotype analysis showed
that only three haplotypes were observed among the donors and
recipients. The frequencies were G-G (45.80 and 41.30 %), A-A
(35.60 and 37.20 %), and A-G (18.60 and 21.50 %).
An analysis of the associations between the CTLA-4 gene
polymorphisms and aGvHD
In a univariate analysis, we found that none of donor poly-
morphisms were associated with susceptibility to aGvHD
(Table 2), although we observed a lower frequency of disease
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in those recipients who were transplanted from the
CT60G>A[AA] donors than in recipients transplanted from
donors possessing the CT60G>A[G+] allele (9.50 vs.
17.30 %).
For recipients with the CT60G>A polymorphism, we found
that it was significantly associated with aGvHD risk (Table 3).
The distribution of genotypes of recipients with the CT60G>A
polymorphism was different in recipients with and without
aGvHD (χ2df=2=9.27, p=0.01, pcorected=0.04), and the presence
of at least one A allele decreased the risk of aGvHD about two-
fold [for CT60G>A[GA], the ORwas 0.47 (95%CI 0.28–0.79),
and for CT60G>A[AA], the ORwas 0.45 (95%CI 0.21–0.98)].
Table 1 Clinical characteristics of recipients according to aGvHD presence
Variable aGvHD (+) aGvHD (−) OR 95 % CI
N % N %
Type of HSCT RD 45 26.30 57 42.50 0.48 0.29–0.78
URD 126 73.70 77 57.50
Σ 171 100 % 134 100 % p=0.004
Conditioning regimen RIC 9 5.30 20 14.90 2.40 1.65–3.48
RTMAC 35 20.5 51 38.1
MAC 127 74.3 63 47
Σ 171 100 % 134 100 % p=0.00001
HLA
mismatch (MM)
MM =0 125 73.10 115 85.80 2.11 1.22–3.62
MM =1 41 24.00 18 13.40
MM =2 5 2.90 1 0.70
Σ 171 100 % 134 100 % p=0.008
Donor-recipient sex disparity F→F 30 17.80 26 19.80 1a –
F→M 30 17.80 26 19.80 1.00 0.48–2.10
M→F 51 30.20 34 26.00 1.30 0.66–2.57
M→M 58 34.30 45 34.40 1.12 0.58–2.15
Σ 169 100 % 131 100 % p=0.85
Relapse Yes 21 14.00 14 11.40 1.27 0.61–2.61
No 129 86.00 109 88.60
Σ 150 100 % 123 100 % p=0.52
Variables aGvHD (+) aGvHD (−) Medians differenced 95 % CI




Q3b 45.00 48.00 p=0.11
Donor age Q1 26.00 24.00 1.87 −1.84–5.73
Median 33.00 32.00
Sn 10.00 10.00
Q3 42.00 41.80 p=0.36
Overall survival for died recipients Q1 2.90 2.52 −1.59 −4.64–2.65
Median 5.43 6.92
Sn 3.95 6.58
Q3 12.64 14.90 p=0.35
Overall survival for living recipients Q1 22.16 23.36 3.73 −6.26–12.89
Median 35.80 31.97
Sn 17.36 14.60
Q3 53.00 43.76 p=0.42
aGvHD acute graft versus host disease, OR odds ratio, CI confidence interval, HSCT hematopoietic stem cell transplantation, HLA human leukocyte
antigen, RD related donor, URD unrelated donor, RIC reduced-intensity conditioning, RTMAC reduced toxicity myeloablative conditioning
a Baseline group
bQ1 and Q3: first and third quartiles
c Sn is the measure of variability
d Case-control bias-corrected difference
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Logistic regression analysis was used to test whether the
association observed between the recipient CT60G>A[GG]
genotype and susceptibility to aGvHD was influenced by oth-
er factors, including HLA matching, conditioning regimen
(MAC, RTMAC, or RIC), graft source (BM or PBPC), mode
of transplantation (related or unrelated donor), diagnosis, re-
cipient age, donor sex, and age. Both recipient and donor
genotypes were included in the analysis to exclude any possi-
ble interaction between them. Themodel, including condition-
ing regimen, type of transplantation (RD vs. URD), and the
recipient CT60G>A polymorphism, fitted the best to the prob-
ability of aGvHD disease.
In this model, the OR increased 2.68-fold from RIC to
RTMAC and from RTMAC to MAC therapy (95 % CI
1.65–4.07, p=0.00003). Transplantation from an unrelated
donor raised the risk of aGvHD 1.87-fold (95 % CI 1.02–
3.24, p=0.04) compared to RD HSCT.
Moreover, the recipient CT60G>A[GG] genotype was
associated with a 2.63 higher aGvHD risk (95 % CI 1.45–
4.59, p= 0.001) than that of CT60G>A[GA] and
CT60G>A[AA]. This means that a recipient possessing at
least one A allele had approximately a twofold reduced
chance of aGvHD compared with a recipient with
CT60G>A[GG] who underwent the same type of transplan-
tation and conditioning regimen.
The expected frequency of aGvHD in relation to the con-
ditioning regimen, the type of HSCT, and the recipients’
CT60G>A genotype are presented in Table 4. The lowest
aGvHD risk group consisted of recipients possessing the
CT60G>A[A+] allele who received a transplant from related
donors (RD HSCT) with RIC conditioning (CT60G>A[A+]/
RD-HSCT/RIC), and it was chosen as the baseline (reference
group) for OR calculations.
The estimated aGvHD frequency in the reference group of
recipients was 10.50 %. The expected frequency of aGvHD
for recipients with the predisposing CT60G>A[GG] genotype
transplanted from a related donor and with the RIC condition-
ing regimen was 23.40 % with an OR of 2.60.
The estimated aGvHD frequency in the recipients with
CT60G>A[A+] transplanted from related donors and treated
with RTMAC gained 23.40 % compared with the reference
group with an OR of 2.60 (conditioning regiment effect). In
the CT60G>A[GG] recipients with RD HSCT and RTMAC
preparation, the frequency increased to 44.3%, with the raised
OR being 6.78 (additive effect of the recipients’ genotype and
the use of RTMAC), whereas in the recipients with the
CT60G>A[GG] genotype transplanted from unrelated donors
with the use of RTMAC, the aGvHD expected frequency was
59.40 % and the OR increased to 12.47 compared with the
reference group.
Consequently, in the highest risk group of recipients with
the predisposing CT60G>A[GG] genotype, transplants from
unrelated donors, and the MAC regimen, the expected fre-
quency of aGvHD was 79.2 % and the OR was as high as
32.46 compared with the reference group (CT60G>A[A+]/
RD-HSCT/RIC) (Table 5).
The effect of the recipient CT60G>A genotype was inde-
pendent of the donor CTLA-4 polymorphism and the age of
the recipients and donors (p=0.39).
The haplotype distribution between groups of recipients
with and without aGvHD was different (χ2df=2=9.60; p=
0.008). Haplotypes G-G and A-G were associated with an
increased risk of aGvHD, whereas haplotype A-Awas protec-
tive against aGvHD (Table 6).
An analysis of the associations between the CTLA-4 gene
polymorphisms and relapse
Relapse occurred in 34 patients, and 27 of them died due to
this complication. None of donors’ and recipients’ genetic
variations and clinical parameters affected the incidence of
relapse (data not shown).
Table 2 Genotypes frequency of
donors’ CTLA-4 SNPs in relation
to aGvHD presence
Donors polymorphisms aGvHD (+) aGvHD (−) OR 95 % CI
N % N %
CTLA-4c.49A>G
(rs231775)
AA 54 32.10 47 35.10 1a – χ2df=2=0.49
p=0.78AG 87 51.80 64 47.80 1.18 0.71–1.96
GG 27 16.10 23 17.20 1.02 0.52–2.02




GG 69 41.10 47 35.30 1a – χ2df=2=4.16
p=0.13GA 83 49.40 63 47.40 0.90 0.55–1.47
AA 16 9.50 23 17.30 0.48 0.23–1.00
Σ 168 100 % 133 100 % – –
HWE p=0.23 p=0.86
aGvHD acute graft versus host disease,OR odds ratio,CI confidence interval,HWEHardy-Weinberg equilibrium
aBaseline group
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An analysis of the associations between the CTLA-4 gene
polymorphisms and overall survival
The median follow-up time was 21.27 months (range,
0.5–67.5 months). In the studied cohort of patients,
201 recipients lived and 111 died during the observa-
tion period. The median overall survival (OS) for all
patients was 23.67 months (quadrille (Q), Q1=8.45;
Q3=40.20). For living patients, the median OS was
34.23 months (Q1=23.36; Q3=50.38), whereas for
dead recipients, the median OS was 5.53 months
(Q1=2.77; Q3=13.48).
None of the donors’ and recipients’ genetic factors and
clinical parameters had an impact on the overall survival
(p=0.49).
Discussion
In early immunogenetic studies in transplantation, genes
encoding HLA were the first targets for donor-recipient
matching because the HLA molecules are crucial for T cell
recognition. During the last several years, growing attention
has been focused on polymorphisms in genes of the KIR fam-
ily (Gagne et al. 2002;Giebel et al. 2009;Ludajic et al. 2009),
as well as on cytokine and cytokine receptor genes (Bogunia-
Kubik 2004;Dickinson and Holler 2008;Karabon et al.
2005;Markey et al. 2008).
Given the importance of co-stimulatory pathways and at-
tempts to use CTLA-4-Ig to prevent GvHD in animal models
(Blazar et al. 1996;Ichiki et al. 2006), several published re-
ports evaluated the association between donor CTLA-4 gene
polymorphisms and outcome after hematopoietic stem cell
transplantation (Bosch-Vizcaya et al. 2012;Iravani-Saadi
et al. 2014;Mossallam and Samra 2013;Perez-Garcia et al.
2009;Piccioli et al. 2010). However, the results presented in
these studies were inconsistent. Predominantly two polymor-
phisms in the CTLA-4 gene were investigated, CTLA-
4c.49A>G and CT60G>A.
The first and the largest study performed on a Spanish
population by Perez Garcia et al. (Perez-Garcia et al. 2007)
indicated that the CTLA-4c.49A>G SNP in RD-HSCT donors
had no impact on aGvHD development, whereas the donor
CT60G>A[AA] genotype was associated with a higher risk of
aGvHD II-IV but with a better 5-year OS and a lower risk of
relapse. The Azarian et al. study (Azarian et al. 2007) showed
no association between the donor CTLA-4c.49A>G and
CT60G>A SNPs and susceptibility to aGvHD in RD-HSCT
in a French population; however, the authors found that the
presence of the G allele in those SNPs increased the risk of
developing chronic GvHD. Based on a study of a Tunisian
Table 3 Genotype frequency of
recipients’ CTLA-4 SNPs
according to aGvHD presence
Recipients polymorphisms aGvHD (+) aGvHD (−) OR 95 % CI
N % N %
CTLA-4c.49A>G
(rs231775)
AA 33 23.60 38 30.60 1a – χ2df=2=3.82
p=0.15AG 76 54.30 69 55.60 1.27 0.72–2.23
GG 31 22.10 17 13.70 2.07 0.98–4.36




GG 69 49.60 39 31.20 1a – χ2df=2=9.27
p=0.04bGA 55 39.60 67 53.60 0.47 0.28–0.79
AA 15 10.80 19 15.20 0.45 0.21–0.98
Σ 139 100 % 125 100 % – –
HWE p=0.43 p=0.36
aGvHD acute graft versus host disease,OR odds ratio,CI confidence interval,HWEHardy-Weinberg equilibrium
aBaseline group
b p value adjusted to number of tests
Table 4 The best regression model of probability of aGvHD syndrome
including the type of HSCT donor (related (RD) vs. unrelated (URD)),
the conditioning regimen (reduced-intensity conditioning (RIC), reduced-
toxicity myeloablative conditioning (RTMAC), and mieloablative condi-
tioning (MAC)), and recipient genotype




URD HSCT 1.87 1.02–3.24 0.04




OR odds ratio, CI confidence interval, HSCT hematopoietic stem cell
transplantation
a CT60G>A[A+]+RD HSCT+ RIC as baseline
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population, Sellami et al. (Sellami et al. 2011) postulated that
the haplotype CTLA-4g.319C>T[C]/CTLA-4c.49A>G[G]
was associated with the incidence of chronic GvHD. The
Vannucchi et al. study (Vannucchi et al. 2007) devoted to
URD HSCT showed no association between CTLA-
4c.49A>G and acute or chronic GvHD, but like the Perez–
Garcia et al. study (Perez-Garcia et al. 2007), it indicated that
the CT60G>A[AA] genotype raised the risk of severe aGvHD
and cGvHD. Similarly, Chien et al. (Chien et al. 2012) pointed
out an association between the CT60G>A polymorphism and
severe aGvHD risk in unrelated bone marrow transplantation.
Different results were obtained by Xiao et al. for a Chinese
population (Xiao et al. 2012). They found that patients receiv-
ing stem cells from related donors with the CT60G>A[AA]
polymorphism had a lower risk of aGvHD grades II–IV.
In contrast, other studies performed on RD HSTC or URD
HSCT in different populations (Spanish, Japanese, and Italian)
reported no association between those polymorphisms and the
aGvHD risk but indicated an effect of those SNPs on the
overall survival or relapse rate (Bosch-Vizcaya et al.
2012;Jagasia et al. 2012;Piccioli et al. 2010).
In our study, we found no impact of donor CTLA-
4c.49A>G and CT60G>A polymorphisms on HSCT out-
come. Like Xiao et al. (Xiao et al. 2012), we observed a not
statistically significant lower frequency of the donor
CT60G>A[AA] genotype than that of the CT60G>A[GG]
genotype in patients with aGvHD.
The reasons for these inconsistencies may include a differ-
ent type of transplantation, a different conditioning regimen,
GvHD prophylaxis, and ethnic background. For example, the
frequency of the CT60G>A[GG] genotype in Polish donors is
approximately 40.00 %, but it is approximately 25.00 % in
Spanish donors (Perez-Garcia et al. 2007). Moreover, in the
Polish population, the frequency of the [GG] genotype is
higher than that of the [AA] genotype, whereas in the Spanish
population a different relationship was observed. Further-
more, in our analysis, we compared the group without aGvHD
symptoms (aGvHD grade 0) to the group with any aGvHD
symptoms (grades I–IV).
CTLA-4 expressed on donors’ Tcells plays the crucial role
in the regulation of the immune response, in particular, in the
graft versus leukemia effect and in controlling infections;
therefore, the majority of studies have focused on the donor
CTLA-4 gene polymorphism. However, a limited number of
studies have highlighted the role of the CTLA-4c.49A>G and
CT60G>A polymorphisms in recipients. Orru et al. (Orru
et al. 2012) showed that in URD transplantation for
Table 5 Development of aGvHD syndrome in group of HSCT
recipients in relation to (A) the type of HSCT donor (related (RD) vs.
unrelated (URD)), the conditioning regimen (reduced-intensity condition-
ing (RIC), reduced-toxicity myeloablative conditioning (RTMAC), and
mieloablative conditioning (MAC)) and the recipient’s genotype
(CT60G>A[GG]); (B) the type of HSCT donor (related vs. unrelated),
and the recipient’s genotype (CT60G>A[GG]); and (C) the recipient’s
genotype (CT60G>A[GG])
A Type of HSCT R CT60G>A[GG] RIC
Yes No % Yes ORa
RD GG 1 7 23.40 2.60
GA/AA 3 3 10.50 1.00
URD GG 3 2 35.90 4.77
GA/AA 0 8 17.80 1.85
Total 7 20 20.00 1b
Type of HSCT R CT60G>A[GG] RTMAC
Yes No % Yes ORa
RD GG 2 6 44.30 6.78
GA/AA 3 13 23.40 2.60
URD GG 15 10 59.40 12.47
GA/AA 10 19 36.00 4.79
Total 30 48 41.10 2.79b
Type of HSCT R CT60G>A[GG] MAC
Yes No % Yes ORa
RD GG 14 6 67.40 17.62
GA/AA 14 17 44.30 6.78
URD GG 33 8 79.20 32.46
GA/AA 38 26 59.40 12.47
Total 99 57 63.50 6.96b
B Type of HSCT R CT60G>A[GG] Yes No % Yes ORc
RD GG 17 19 52.20 2.28
GA/AA 20 33 32.40 1.00
URD GG 51 20 70.40 4.96
GA/AA 48 53 47.70 1.90
C R CT60G>A[GG] Yes No % Yes ORd
GG 68 39 65.90 2.63
GA/AA 68 86 42.30
Percent of cases (% Yes) and odds ratios (ORs) are estimated based on
model
HSCT hematopoietic stem cell transplantation
a RD & GA/AA & RIC as baseline
b Total RIC as baseline
c RD & GA/AA as baseline
dGA/AA as baseline
Table 6 Haplotypes frequency ofCTLA-4 gene polymorphisms among
HSCT recipients in relation to aGvHD
CTLA-4c.49A>G CT60G>A aGvHD (+) aGvHD (−) RRa
G G 50.00 41.80 1.20
A A 29.30 42.20 0.69
A G 20.70 16.00 1.29
χ2df=2=9.60; p=0.008 100 % 100 % –
aGvHD acute graft versus host disease, HSCT hematopoietic stem cell
transplantation
a RR—relative risk cases/controls
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thalassemia patients from Italy, the recipient CT60G>A[AA]
genotype was associated with a higher risk of aGvHD grade II
or higher. In addition, Picciolli et al. (Piccioli et al. 2010)
found that the recipient CTLA-4c.49A>G but not CT60G>A
was a risk factor for aGvHD in an Italian population, whereas
Xiao et al. (Xiao et al. 2012) in a Chinese population and
Mosssallam et al. in a Tunesian population (Mossallam and
Samra 2013) found no effect of the recipientCTLA-4c.49A>G
and CT60G>A SNPs on aGvHD risk.
In the present study, we showed by a univariate analysis
that the CT60G>A[GG] genotype was associated with ap-
proximately a twofold higher risk of aGvHD compared with
the CT60G>A[GA] and CT60G>A[AA] genotypes. The mul-
tivariate analysis, which included known aGvHD risk factors,
showed that the CT60G>A[GG] genotype, together with the
type of transplantation and aggressiveness of the conditioning
regimen, was an independent risk factor for this complication.
We found that patients who were recipients of the
CT60G>A[GG] genotype transplanted from unrelated donors
and who received the myeloablative conditioning regimen had
more than a 30-fold higher risk of aGvHD than patients who
received at least one A allele transplanted from related donors
and who received a reduced toxicity conditioning regimen.
The presence of the G allele of both the CTLA-4c.49A>G
and CT60G>A polymorphisms has been reported to be asso-
ciated with the risk of many autoimmune diseases, including
coeliac disease, systemic lupus erythematosus, multiple scle-
rosis, chronic inflammatory arthropathies, Sjogren syndrome,
and autoimmune thyroiditis (Gough et al. 2005;Kavvoura
et al. 2007;Kavvoura and Ioannidis 2005).
Here, we postulate that the presence of the CT60G>A[GG]
genotype in recipients is associated with an impaired regula-
tion of T cell activation and that it promotes the development
of aGvHD.
On the basis of current knowledge, it is difficult to explain
the role of the recipient CTLA-4 gene polymorphisms in the
development of aGvHD. One possible explanation is that the
CTLA-4 molecules present on surviving host T cell popula-
tions, including recipient lymphocytes, leukemic monocytes,
and especially T reg cells, may contribute to the clinical out-
come after HSCT (Bayer et al. 2009;Laurent et al.
2010;Pistillo et al. 2003). Moreover, our functional study
showed that the recipients’ pretransplant CTLA-4 mRNA lev-
el and protein expression were associated with aGvHD risk
(Karabon et al. 2015).
The limitation of this study is the heterogenic group of
donor-recipient pairs; however, we believe that the implemen-
tation of a multivariate logistic regression analysis, which in-
cludes other prognostic factors for aGvHD development, al-
lows us to overcome this weakness of the study.
Probably due to the low relapse rate observed in our cohort
of patients, we were not able to find any association between
donor and recipient CTLA-4 gene polymorphisms and
aGvHD. We also did not find any association between the
SNPs investigated here and OS. The data presented in the
literature regarding the association of CTLA-4c.49A>G and
CT60G>Awith relapse risk and overall survival were incon-
sistent, which was clearly summarized by Mossallam et al.
(Mossallam and Samra 2013).
Conclusion
Our data suggest that the recipient CT60G>A[GG] genotype
has an impact on aGvHD development, especially in patients
who receive transplants from unrelated donors and who re-
ceive myeloablative conditioning.
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